Clinical Trials Browser

Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT06988475 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

NCT05243641 2025-06-11

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1/2 Terminated

10 enrolled 11 charts

Breast

Breast Neoplasms

NCT03192501 2024-06-25

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Recruiting

250 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT05567055 2024-06-17

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Phase 1 Terminated

3 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Phase 1 Completed

65 enrolled

CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

NCT05154344 2023-01-06

CapmATU

Completed

182 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02750215 2022-03-14

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Phase 2 Completed

20 enrolled 19 charts

Malignant Non-small Cell Neoplasm of Lung Stage IV

NCT01911507 2021-10-13

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Phase 2 Terminated

1 enrolled 7 charts

Dermatologic

Noonan Syndrome 6, Melanoma

NCT03693339 2018-10-03

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Phase 2 Unknown

27 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

ESMART

DETERMINE

DETERMINE

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

CapmATU

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation